Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia

Figure 6

Cumulative probability of patient survival by (a) regimen, (b) cycles covered, and (c) cumulative dose received in the South Western Sydney between 2011 and 2015. Patients who received FOLFOX survived longer compared to XELOX (median value: 11.5 months vs. 9 months; n = 211 vs. n = 105, respectively). The vertical dotted lines indicate median survival time for each group.

(a)

(b)

(c)